With clinical data beginning to emerge, big pharma is signaling its belief that in vivo CAR generation is the next immunotherapy breakthrough.
OXB announces date for Capital Markets Day and participation in upcoming investor conferences Oxford, UK – 3 March 2026: OXB ...
ReiThera, the Italian leading Contract Development and Manufacturing Organization (CDMO) specialized in the development and GMP manufacturing of viral vectors for gene therapies and vaccines, is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results